Joinn Laboratories(China)Co.,Ltd.

Equities

603127

CNE100002W27

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
17.45 ^CNY	-3.96%		+6.47%	-26.40%

Apr. 30	Nomura Adjusts Joinn Laboratories’ Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral	MT
Apr. 30	Nomura Adjusts Joinn Laboratories’ Price Target to HK$10.41 From HK$12.60, Keeps at Neutral	MT

Joinn Laboratories Co.,Ltd. entered into an agreement to acquire Yunnan Yinmore Bio-Tech Co., Ltd from Yunnan Yinmore Group Co., Ltd. for approximately CNY 840 million.

April 27, 2022

Joinn Laboratories (China) Co.,Ltd. (SHSE:603127) entered into an agreement to acquire Yunnan Yinmore Bio-Tech Co., Ltd from Yunnan Yinmore Group Co., Ltd. for approximately CNY 840 million on April 28, 2022. Joinn Laboratories board of director approved the transaction.

Latest news about Joinn Laboratories(China)Co.,Ltd.

Nomura Adjusts Joinn Laboratories’ Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral	Apr. 30	MT
Nomura Adjusts Joinn Laboratories’ Price Target to HK$10.41 From HK$12.60, Keeps at Neutral	Apr. 30	MT
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Tranche Update on Joinn Laboratories(China)Co.,Ltd.'s Equity Buyback Plan announced on April 3, 2024.	Apr. 02	CI
Joinn Laboratories(China)Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Apr. 02	CI
Joinn Laboratories' Profit Slumps 63% in 2023, Misses Estimates	Mar. 31	MT
Joinn Laboratories(China)Co.,Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 30 August 2024	Mar. 28	CI
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Joinn Laboratories(China)Co.,Ltd. authorizes a Buyback Plan.	Mar. 27	CI
MSCI to Remove 74 Companies From China Onshore Index Including China Southern Airlines, Weibo, Greentown China	Feb. 14	MT
Joinn Laboratories’ Actual Controller Receives Warning From Beijing Securities Regulator	Feb. 12	MT
Nomura Downgrades Joinn Laboratories (China) to Neutral From Buy, Adjusts Price Target to HK$12.60 From HK$20.93	Jan. 24	MT
Nomura Downgrades Joinn Laboratories (China) to Neutral From Buy, Adjusts Price Target to 21.01 Yuan From 35 Yuan	Jan. 24	MT
Joinn Laboratories' 2023 Attributable Profit Seen to Decline; Shanghai Shares Fall 5%	Jan. 23	MT
Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	Jan. 23	CI
Joinn Laboratories' Q3 Profit Falls 9%	23-10-31	MT
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Nomura Adjusts Joinn Laboratories' Price Target to 35 Yuan From 34.52 Yuan, Keeps at Buy	23-10-25	MT
Nomura Adjusts Joinn Laboratories (China)'s Price Target to HK$20.93 From HK$20.64, Keeps at Buy	23-10-25	MT
Nomura Adjusts Joinn Laboratories China's Price Target to HK$20.64 From HK$31.23, Keeps at Buy	23-09-01	MT
Nomura Adjusts Joinn Laboratories China's Price Target to 34.52 Yuan From 49.19 Yuan, Keeps at Buy	23-09-01	MT
Joinn Laboratories' H1 Attributable Profit Falls 76%	23-08-31	MT
Joinn Laboratories(China)Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Joinn Laboratories (China) Expects Up to 80% Decline in First-Half Profit	23-07-19	MT
Joinn Laboratories Expects First-Half Profit to Decline Up to 80%	23-07-17	MT

Chart Joinn Laboratories(China)Co.,Ltd.

Duration

Period

More charts

Company Profile

Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The Company conducts its businesses both in the domestic market and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Joinn Laboratories(China)Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.45 CNY

Average target price

18.66 CNY

Spread / Average Target

+6.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
JOINN LABORATORIES(CHINA)CO.,LTD.	-26.40%	1.67B
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research